What is CDT stock price today?

CDT (Cdt Equity Inc) stock is trading at $1.04 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CDT stock going up or down today?

CDT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CDT stock now?

The decision to buy CDT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CDT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CDT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CDT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CDT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CDT's P/E ratio?

P/E ratio data for CDT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CDT's market cap?

CDT (Cdt Equity Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is CDT's price to book ratio?

CDT trades at a price-to-book (P/B) ratio of 5.16, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CDT pay dividends?

CDT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CDT's dividend yield?

CDT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CDT stock a good long-term investment?

CDT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CDT's revenue growth rate?

Revenue growth data for CDT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for CDT are available on our dashboard with complete income statement analysis.

What are the risks of investing in CDT?

Key risks for CDT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CDT compare to its competitors?

Compare CDT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CDT's performance and positioning.

What is CDT's stock price target for 2026?

Our AI model provides price targets for CDT based on fundamental analysis: Bull case $1.35 (+30%), Base case $1.20 (+15%), Bear case $0.94 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CDT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CDT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CDT's next earnings report?

CDT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CDT - Cdt Equity Inc

NYSE * Health Care * Biotechnology

$1.04

+$0.09 (+9.46%)

About Cdt Equity Inc

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

CDT Key Statistics

Market Cap

$5.05M

P/B Ratio

5.16

EPS

$-1177.89

Employees

How CDT Compares to Peers

CDT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CDT(This stock)	$5.05M	N/A	0%	0.0%	-
AMGNAmgen Inc	$181.77B	23.4	0%	0.2%	vs AMGN
GILDGilead Sciences	$166.90B	18.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.59B	26.5	0%	0.4%	vs VRTX
REGNRegeneron Pharmaceuticals	$64.45B	15.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.94B	21.1	0%	0.1%	vs BIIB

Cdt Equity Inc Company Information

Headquarters: California; U.S.A
Website: www.cdtequity.com
Sector: Health Care
Industry: Biotechnology

Data Updated: June 1, 2026 at 11:10 AM EDT

Ready to invest in CDT?

Commission-free trading available. Affiliate links.

Upcoming Events for CDT

Dashboard

Enter a ticker to analyze